ONCAlert | 2018 ASCO Annual Meeting

Results of the LATITUDE Trial in High-Risk Metastatic Hormone-Naive Prostate Cancer

Kim Chi, MD
Published Online: 9:51 PM, Sun June 4, 2017

Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
 

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.